Synairgen PLC 2020 AR2
The report highlights Synairgen plc's significant operational and financial progress during the fiscal year 2020, driven by its response to the COVID-19 pandemic. The company advanced clinical trials for its inhaled interferon beta candidate (SNG001), reporting positive Phase II results and initiating a global Phase III trial. Financially, Synairgen raised £101 million through equity issues to fund its clinical and manufacturing scale-up activities, ending the year with a robust cash balance of £75.0 million.
Company: Synairgen PLC
Sector: Health Care
Country: United Kingdom
Year: 2020
Type: AR2
Pages: 33
Synairgen PLC
Annual Report And Accounts
The report highlights Synairgen plc's significant operational and financial progress during the fiscal year 2020, driven by its response to the COVID-19 pandemic. The company advanced clinical trials for its inhaled interferon beta candidate (SNG001), reporting positive Phase II results and initiating a global Phase III trial. Financially, Synairgen raised £101 million through equity issues to fund its clinical and manufacturing scale-up activities, ending the year with a robust cash balance of £75.0 million.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees